AR and metastatic prostate carcinoma: For instance, metastatic prostate cancer has typically been categorized based on the androgen receptor (AR) activity or neuroendocrine (NE) program: the less aggressive AR+/NE– (AR prostate cancer, ARPC) and the highly aggressive AR–/NE+ (NE prostate cancer, NEPC; Beltran et al., 2016).